In 2023, the reimbursed pharmaceutical market volume in Türkiye stood at 60.3 units of generics. Analyzing trends from 2013 to 2023, we observe modest growth with significant variations. In the early years, year-on-year growth rates oscillated around 1%, but more marked increases were seen in 2016 and 2019. However, minor contractions occurred in 2020 and 2021. The overall compound annual growth rate (CAGR) for the past five years averaged modestly at 0.23%.

Looking forward from 2024, forecasted data suggest a slight uptick in growth, with a 5-year CAGR of 0.36% up to 2028, reflecting a continued but gradual increase in market volume.

Future trends to watch for:

Impact of healthcare policies and reforms in Türkiye.
Technological advancements and their integration into pharmaceutical manufacturing and distribution.
International market dynamics and their influence on the domestic market.
Trends in generics adoption and patient preference shifts.